Patent application number | Description | Published |
20080314740 | Ozone Generating Electrolysis Cell - The ozone generating electrolysis cell ( | 12-25-2008 |
20090098029 | METHOD OF FORMING A SEALED CHANNEL OF A MICROFLUIDIC REACTOR AND A MICROFLUIDIC REACTOR COMPRISING SUCH CHANNEL - In a method according to the invention for forming a sealed channel ( | 04-16-2009 |
20090101519 | FLOW-TYPE LABORATORY OZONOLYSIS APPARATUS AND METHOD OF PERFORMING OZONOLYSIS REACTION - A flow-type laboratory scale ozonolysis apparatus ( | 04-23-2009 |
20090242391 | Electrode for Electrochemical Cell Operating With High Differential Pressure Difference, Procedure for the Manufacturing of Such Electrode and Electrochemical Cell for the Use of Such Electrode - The invention relates to a porous electrode used in an electrochemical cell, containing a carrier and/or catalytic agent, which is characterised by that it consists of two or more layers with different average pore sizes, out of which layers the contact layer with the smallest average pore size is in contact with the membrane, and one or more supporting layers with a greater average pore size are linked to the other side of this contact layer. Furthermore, the invention relates to a procedure for the manufacturing of such electrodes and to electrochemical cells containing such electrodes. | 10-01-2009 |
20110034704 | LABORATORY SCALE CONTINUOUS FLOW HYDROGENATION PROCESS - A process for hydrogenating a sample in a pressure range below supercritical pressure values includes supplying at least a solvent of the sample to be hydrogenated by a feed pump with a constant volume rate into a flow path to create a base solution; adding the sample being dissolved into the flow path; feeding hydrogen into the flow path through a valve configured to transmit hydrogen only into a single direction; leading the dissolved sample in the presence of a catalyst through a hydrogenation reactor, where the reactor is inserted into a section of the flow path located after the hydrogen feeding position; maintaining the pressure of the reaction in a given pressure range by element of a pressure-adjusting unit, and collecting a hydrogenate formed within the hydrogenation reactor in a product receptacle connected to the end of the flow path. | 02-10-2011 |
20110104043 | INSTRUMENT AND PROCESS FOR NANOPARTICLES PRODUCTION IN CONTINUOUS FLOW MODE - The subject of the invention is the ( | 05-05-2011 |
20120128740 | NANOSTRUCTURED SILDENAFIL BASE, ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND CO-CRYSTALS, COMPOSITIONS OF THEM, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention is directed to nanostructured (nanoparticulated) Sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions containing them, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions containing them according to the invention have an average particle size of less than about 500 nm. Sildenafil citrate is inhibiting cGMP specific phosphodiesterase type 5 (PDEV), an enzyme that regulates blood flow in the penis. The compositions of the invention are useful in the treatment of male or female sexual dysfunction and pulmonary arterial hypertension (PAH). | 05-24-2012 |
20120135053 | NANOPARTICULATE TELMISARTAN COMPOSITIONS AND PROCESS FOR THE PREPARATION THEREOF - The present invention is directed to nanostructured (nanoparticulated) Telmisartan compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Telmisartan according to the invention have an average particle size of less than about 600 nm. Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. | 05-31-2012 |
20120141561 | NANOPARTICULATE CANDESARTAN CILEXITIL COMPOSITIONS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention is directed to nanostructured (nanoparticulated) Candesartan or its pharmaceutically acceptable ester, preferable Candesartan Cilexetil, or co-crystal compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Candesartan or its pharmaceutically acceptable ester, preferable Candesartan Cilexetil, or co-crystal according to the invention have an average particle size of less than about 500 nm. Candesartan Cilexetil is a prodrug, is hydrolyzed to Candesartan during absorption from the gastrointestinal tract. Candesartan is a selective AT1 subtype angiotensin II receptor antagonist. | 06-07-2012 |
20120148637 | NANOPARTICULATE OLMESARTAN MEDOXOMIL COMPOSITIONS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention is directed to nanostructured (nanoparticulated) Olmesartan or its pharmaceutically acceptable ester, preferable Olmesartan Medoxomil, or co-crystal compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Olmesartan or its pharmaceutically acceptable ester, preferable Olmesartan Medoxomil, or co-crystal according to the invention have an average particle size of less than about 500 nm. Olmesartan Medoxomil is an angiotensin II receptor antagonist used to treat high blood pressure. The prodrug Olmesartan Medoxomil is marketed worldwide by Daiichi Sankyo, Ltd. and in the United States by Daiichi Sankyo, Inc. | 06-14-2012 |
20130202706 | NANOSTRUCTURED ATORVASTATIN, ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND COMPOSITIONS OF THEM, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention is directed to nanostructured Atorvastatin, its pharmaceutically acceptable salts and compositions of them, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Atorvastain, its pharmaceutically acceptable salts and compositions of them according to the invention have an average particle size of less than about 600 nm. The stable amorphous nanostructured particles of the present invention are characterized by increased solubility and bioequivalent biological performance compared to the marketed crystalline drug. Atorvastatin is a member of the drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque and prevents strokes through anti-inflammatory and other mechanisms. | 08-08-2013 |
20130209521 | NANOSTRUCTURED APREPITANT COMPOSITIONS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention is directed to nanostructured Aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Aprepitant according to the invention have an average particle size of less than about 200 nm. The stable nanostructured particles of the invention are presented by increased solubility, dissolution rate, permeability and bioequivalent or enhanced biological performance characterized by significantly decreased fed/fasted effect compared to the reference and marketed drug. Aprepitant is a chemical compound that belongs to a class of drugs called substance P antagonists (SPA). It mediates its effect by acting on neurokinin 1 receptor. Aprepitant is manufactured by Merck & Co. under the brand name Emend for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting. | 08-15-2013 |
20130210794 | NANOSTRUCTURED EZETIMIBE COMPOSITIONS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention is directed to nanostructured Ezetimibe compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Ezetimibe according to the invention have an average particle size of less than about 400 nm. The stable nanostructured particles of the invention are presented by increased solubility, dissolution rate, permeability and bioequivalent or enhanced biological performance compared to the marketed drug. Ezetimibe is an anti-hyperlipidemic medication that is used to lower cholesterol levels. It acts by decreasing cholesterol absorption in the intestine. | 08-15-2013 |